

I. In the Claims (Clean Sheet)

5mb
D1/

C1

2. A peptide consisting of 16 to 55 amino acid residues, comprising at least one of the amino acid sequences YKLVCYYTWSQYREG (SEQ ID NO: 1), YTSWSQYREGDGSCFR (SEQ ID NO: 2), LDRFLCTHIIYSFANI (SEQ ID NO: 5), THIIYSFANISNDHID (SEQ ID NO: 6), PNLKTLLSVGGWNFGS (SEQ ID NO: 12), NTQSRRTNIKSVPPFL (SEQ ID NO: 16), TFIKSVPPFLRTHGFD (SEQ ID NO: 17), PPFLRTHGFDGLDLAW (SEQ ID NO: 18), HGFDGLDLAWLYPGRR (SEQ ID NO: 19), DLAWLYPGRRDKQHFT (SEQ ID NO: 20), TIDSSYDIAKISQHLD (SEQ ID NO: 28), DIAKISQHLD FISIMT (SEQ ID NO: 29), QHLD FISIMTYDFHGA (SEQ ID NO: 30), SPLFRGQEDASPD RFS (SEQ IS NO: 34), DYAVGYMLRLGAPASK (SEQ ID NO: 37), MLRLGAPASKLVMGIP (SEQ ID NO: 38), PASKLVMGIPTFGRSF (SEQ ID NO: 39), GTLAYYEICDFLRGAT (SEQ ID NO: 46), EICDFLRGATVHRTL G (SEQ ID NO: 47), RGATVHRTL GQQVPYA (SEQ ID NO: 48), VKSKVQYLKDRQLAGA (SEQ ID NO: 53), YLKDRQLAGAMVWALD (SEQ ID NO: 54), LAGAMVWALDLDDFQG (SEQ ID NO: 55), WALDLDDFQGSFCGQD (SEQ ID NO: 56) and DFQGSFCGQDLRFPLT (SEQ ID NO: 57).

3. The peptide according to claim 2, comprising at least one of the amino acid sequences YKLVCYYTWSQYREG (SEQ ID NO: 1), YTSWSQYREGDGSCFP (SEQ ID NO: 2), LDRFLCTHIIYSFANI (SEQ ID NO: 5), THIIYSFANISNDHID (SEQ ID NO: 6), PNLKTLLSVGGWNFGS (SEQ ID NO: 12), QHLD FISIMTYDFHGA (SEQ ID NO: 30), SPLFRGQEDASPD RFS (SEQ ID NO: 34), DYAVGYMLRLGAPASK (SEQ ID NO: 37), MLRLGAPASKLVMGIP (SEQ ID NO: 38), YLKDRQLAGAMVWALD (SEQ ID NO: 54) and LAGAMVWALDLDDFQG (SEQ ID NO: 55)..

7. A pharmaceutical composition comprising one or more peptides according to claim 2, and a pharmaceutically acceptable carrier.

11. A test kit for use in the detection of activated autoreactive T cells, comprising one or more peptides according to claim 2.

Sub
D4
C2

13. A pharmaceutical composition consisting of one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising at least one of the amino acid sequences YKLVCYYTSWSQYREG (SEQ ID NO:1), YTSWSQYREGDGSCFP (SEQ ID NO:2), LDRFLCTHIIYSFANI (SEQ ID NO:5), THIIYSFANISNDHID (SEQ ID NO:6), PNLKTLLSVGGWNFGS (SEQ ID NO:12), NTQSRRTFIKSVPPFL (SEQ ID NO:16), TFIKSVPPFLRTHGFD (SEQ ID NO:17), PPFLRTHGFDGLDLAW (SEQ ID NO:18), HGFDGLDLAWLYPGRR (SEQ ID NO:19), DLAWLYPGRRDKQHFT (SEQ ID NO:20), TIDSSYDIAKISQHLD (SEQ ID NO:28), DIAKISQHLD FISIMT (SEQ ID NO:29), QHLD FISIMTYDFHGA (SEQ ID NO:30), SPLFRGQEDASPDRFS (SEQ ID NO:34), DYAVGYMLRLGAPASK (SEQ ID NO:37), MLRLGAPASKLVMGIP (SEQ ID NO:38), PASKLVMGIPTFGRSF (SEQ ID NO:39), GTLAYYEICDFLRGAT (SEQ ID NO:46), EICDFLRGATVHRTL (SEQ ID NO:47), RGATVHRTL GQQVPYA (SEQ ID NO:48), VKSKVQYLKDRQLAGA (SEQ ID NO:53), YLKDRQLAGAMVWALD (SEQ ID NO:54), LAGAMVWALD LDDFQG (SEQ ID NO:55), WALD LDDFQGSFCGQD (SEQ ID NO:56) or DFQGSFCGQDLRFPLT (SEQ ID NO:57).

C3

LDRFLCTHIIYSFANI (SEQ ID NO:5), THIIYSFANISNDHID (SEQ ID NO:6), QHLD FISIMTYDFHGA (SEQ ID NO:30), SPLFRGQEDASPDRFS (SEQ ID

Sub D4
(SEQ ID NO:38), YLKDRQLAGAMVWALD (SEQ ID NO:54) and
LAGAMVWALDLDDFQG (SEQ ID NO:55).

C4
15. A method of inducing systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition comprising one or more peptides containing 16 to 55 amino acid residues selected from the group consisting of at least one of the amino acid sequences LVCYYTSYS (SEQ ID NO:60), FLCTHIIYS (SEQ ID NO:61), IIYSFANIS (SEQ ID NO:62), LKTLLSVGG (SEQ ID NO:63), FIKSVPPFL (SEQ ID NO:64), FDGLDLAWL (SEQ ID NO:65), FIKSVPPFL (SEQ ID NO:66), YDIAKISQH (SEQ ID NO:67), LDFISIMTY (SEQ ID NO:68), FISIMTYDF (SEQ ID NO:69), FRGQEDASP (SEQ ID NO:70), YAVGYMLRL (SEQ ID NO:71), MLRLGAPAS (SEQ ID NO:72), LAYYEICDF (SEQ ID NO:73), LRGATVHRT (SEQ ID NO:74), YKLDRQLAG (SEQ ID NO:75), LAGAMVWAL (SEQ ID NO:76), VWALDLDDF (SEQ ID NO:77) or LDLDDFQGS (SEQ ID NO:78), and a pharmaceutically acceptable carrier.

16. A method for inducing a systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 13.

17. A method for inducing a systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition according to claim 14.

C5
18. A test kit for use in the detection of activated autoreactive T cells, comprising one or more peptides consisting of 16 to 55 amino acid residues, comprising at least one of the amino acid sequences YKLVCYYTSWSQYREG (SEQ ID NO: 1), YTSWSQYREGDGSCFE (SEQ ID NO: 2), LDRFLCTHIIYSFANI

C5

(SEQ ID NO: 5), THIIYSFANISNDHID (SEQ ID NO: 6),
PNLKTLLSVGGWNFGS (SEQ ID NO: 12), NTQSRRTFIKSVPPFL (SEQ
ID NO: 16), TFIKSVPPFLRTHGFD (SEQ ID NO: 17),
PPFLRTHGFDGLDLAW (SEQ ID NO: 18), HGI'DGLDLAWLYPGRR
(SEQ ID NO: 19), DLAWLYPGRRDKQHFT (SEQ ID NO: 20),
TIDSSYDIAKISQHLD (SEQ ID NO: 28), DIAKISQHLD FISIMT (SEQ ID
NO: 29), QHLDFISIMTYDFHGA (SEQ ID NO: 30),
SPLFRGQEDASPD RFS (SEQ ID NO: 34), DYAVGYMLRLGAPASK (SEQ
ID NO: 37), MLRLGAPASKLVMGIP (SEQ ID NO: 38),
PASKLVMGIPTFGRSF (SEQ ID NO: 39), GTLAYYEICDFLRGAT (SEQ
ID NO: 46), EICDFLRGATVHRTLG (SEQ ID NO: 47),
RGATVHRTLGQQVPYA (SEQ ID NO: 48), VKSKVQYLKDRQLAGA
(SEQ ID NO: 53), YLKDRQLAGAMVWALD (SEQ ID NO: 54),
LAGAMVWALDLDDFQG (SEQ ID NO: 55), WALDLDDFQGSFCGQD
(SEQ ID NO: 56) and DFQGSFCGQDLRFPLT (SEQ ID NO: 57).

II. In the Claims (Marked Version)

Please add the following Claims:

18. A test kit for use in the detection of activated autoreactive T cells, comprising one or more peptides consisting of 16 to 55 amino acid residues, comprising at least one of the amino acid sequences YKLCVYYTWSQYREG (SEQ ID NO: 1), YTSWSQYREGDGSCFP (SEQ ID NO: 2), LDRFLCTHIIYSFANI (SEQ ID NO: 5), THIIYSFANISNDHID (SEQ ID NO: 6), PNLKTLLSVGGWNFGS (SEQ ID NO: 12), NTQSRRTFIKSVPPFL (SEQ ID NO: 16), TFIKSVPPFLRTHGFD (SEQ ID NO: 17), PPFLRTHGFDGLDLAW (SEQ ID NO: 18), HGFDGLDLAWLYPGRR (SEQ ID NO: 19), DLAWLYPGRRDKQHFT (SEQ ID NO: 20), TIDSSYDIAKISQHLD (SEQ ID NO: 28), DIAKISQHLD FISIMT (SEQ ID NO: 29), QHLD FISIMTYDFHGA (SEQ ID NO: 30), SPLFRGQEDASPD RFS (SEQ ID NO: 34), DYAVGYMLRLGAPASK (SEQ ID NO: 37), MLRLGAPASKLVMGIP (SEQ ID NO: 38), PASKLVMGIPTFGRSF (SEQ ID NO: 39), GTLAYYEICDFLRGAT (SEQ ID NO: 46), EICDFLRGATVHRTL G (SEQ ID NO: 47), RGATVHRTL GQQVPYA (SEQ ID NO: 48), VKSKVQYKDRQLAGA (SEQ ID NO: 53), YLKDRQLAGAMVWALD (SEQ ID NO: 54), LAGAMVWALDLDDFQG (SEQ ID NO: 55), WALDLDDFQGSFCGQD (SEQ ID NO: 56) and DFQGSFCGQDLRFPLT (SEQ ID NO: 57).

Please amend the Claims as follows:

2. (Amended) A peptide [having] consisting of 16 to 55 amino acid residues, comprising at least one of the amino acid sequences YKLCVYYTWSQYREG (SEQ ID NO: 1), YTSWSQYREGDGSCFP (SEQ ID NO: 2), LDRFLCTHIIYSFANI (SEQ ID NO: 5), THIIYSFANISNDHID (SEQ ID NO:

6), PNLKTLLSVGGWNFGS (SEQ ID NO: 12), NTQSRRTFIKSVPPFL (SEQ ID NO: 16), TFIKSVPPFLRTHGFD (SEQ ID NO: 17), PPFLRTHGFDGLDLAW (SEQ ID NO: 18), HGFDGLDLAWLYPGRR (SEQ ID NO: 19), DLAWLYPGRRDKQHFT (SEQ ID NO: 20), TIDSSYDIAKISQHLD (SEQ ID NO: 28), DIAKISQHLD FISIMT (SEQ ID NO: 29), QHLD FISIMTYDFHGA (SEQ ID NO: 30), SPLFRGQEDASPDRFS (SEQ ID NO: 34), DYAVGYMLRLGAPASK (SEQ ID NO: 37), MLRLGAPASKLVMGIP (SEQ ID NO: 38), PASKLVMGIPTFGRSF (SEQ ID NO: 39), GTLAYYEICDFLRGAT (SEQ ID NO: 46), EICDFLRGATVHRTL G (SEQ ID NO: 47), RGATVHRTL GQQVPYA (SEQ ID NO: 48), VKSKVQYLKDRQLAGA (SEQ ID NO: 53), YLKDRQLAGAMVWALD (SEQ ID NO: 54), LAGAMVWALDLDDFQG (SEQ ID NO: 55), WALDLDDFQGSFCGQD (SEQ ID NO: 56) and DFQGSFCGQDLRFPLT (SEQ ID NO: 57).

13. (Amended) A pharmaceutical composition [comprising] consisting of one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising at least one of the amino acid sequences YKLVCCYYTSWSQYREG (SEQ ID NO:1), YTSWSQYREGDGSCFP (SEQ ID NO:2), LDRFLCTHIIYSFANI (SEQ ID NO:5), THIIYSFANISNDHID (SEQ ID NO:6), PNLKTLLSVGGWNFGS (SEQ ID NO:12), NTQSRRTFIKSVPPFL (SEQ ID NO:16), TFIKSVPPFLRTHGFD (SEQ ID NO:17), PPFLRTHGFDGLDLAW (SEQ ID NO:18), HGFDGLDLAWLYPGRR (SEQ ID NO:19), DLAWLYPGRRDKQHFT (SEQ ID NO:20), TIDSSYDIAKISQHLD (SEQ ID NO:28), DIAKISQHLD FISIMT (SEQ ID NO:29), QHLD FISIMTYDFHGA (SEQ ID NO:30), SPLFRGQEDASPDRFS (SEQ ID NO:34), DYAVGYMLRLGAPASK (SEQ ID NO:37), MLRLGAPASKLVMGIP (SEQ ID NO:38), PASKLVMGIPTFGRSF (SEQ ID NO:39), GTLAYYEICDFLRGAT (SEQ ID NO:46), EICDFLRGATVHRTL G (SEQ ID NO:47), RGATVHRTL GQQVPYA (SEQ ID NO:48), VKSKVQYLKDRQLAGA (SEQ ID NO:53), YLKDRQLAGAMVWALD (SEQ ID NO:54), LAGAMVWALDLDDFQG (SEQ ID

NO:55), WALDLDDFQGSFCGQD (SEQ ID NO:56) or DFQGSFCGQDLRFPLT (SEQ ID NO:57).

14. (Amended) A pharmaceutical composition [comprising] consisting of one or more peptides selected from the group consisting of peptides containing 16 to 55 amino acid residues and comprising at least one of the amino acid sequences YKLVCYYTSWSQYREG (SEQ ID NO:1), YTSWSQYREGDGSCFP (SEQ ID NO:2), LDRFLCTHIIYSFANI (SEQ ID NO:5), THIIYSFANISNDHID (SEQ ID NO:6), QHLDFISIMTYDFHGA (SEQ ID NO:30), SPLFRGQEDASPD RFS (SEQ ID NO:34), DYAVGYMLRLGAPASK (SEQ ID NO:37), MLRLGAPASKLVMGIP (SEQ ID NO:38), YLKDRQLAGAMVWALD (SEQ ID NO:54) and LAGAMVWALDLDDFQG (SEQ ID NO:55).

15. (Twice Amended) A method of inducing systemic immunological tolerance, comprising administering to a patient in need thereof a pharmaceutical composition comprising one or more peptides [selected from the group consisting of peptides] containing 16 to 55 amino acid residues selected from the group consisting of [and comprising] at least one of the amino acid sequences LVCYYTSYS (SEQ ID NO:60), FLCTHIIYS (SEQ ID NO:61), IIYSFANIS (SEQ ID NO:62), LKTLLSVGG (SEQ ID NO:63), FIKSVPPFL (SEQ ID NO:64), FDGLDLAWL (SEQ ID NO:65), FIKSVPPFL (SEQ ID NO:66), YDIAKISQH (SEQ ID NO:67), LDFISIMTY (SEQ ID NO:68), FISIMTYDF (SEQ ID NO:69), FRGQEDASP (SEQ ID NO:70), YAVGYMLRL (SEQ ID NO:71), MLRLGAPAS (SEQ ID NO:72), LAYYEICDF (SEQ ID NO:73), LRGATVHRT (SEQ ID NO:74), YKLDRQLAG (SEQ ID NO:75), LAGAMVWAL (SEQ ID NO:76), VWALDLDDF (SEQ ID NO:77) or LDLDDFQGS (SEQ ID NO:78), and a pharmaceutically acceptable carrier.